Ahmed Maher
Cairo, Cairo Governorate, 11757, Egypt
NCT Number: NCT05921370
Selective alpha-blockers have been used for the treatment of ureteric stones as medical expulsive therapy (MET). Recently they have been successfully used in passive ureteric dilatation before semirigid ureteroscopy. This study enables us to know the role of silodosin in ureteric dilatation to facilitate ureteral access sheath placement in Retrograde Intrarenal Surgery with flexible ureteroscopy.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 3
Cairo, Cairo Governorate, 11757, Egypt
The ureteral access sheaths (UAS) used during Retrograde Intrarenal Surgery (RIRS) were produced for easy access to the upper urinary tract. The main advantages of UAS are providing repetitive access to the ureteral and collecting duct system, decreasing intrarenal pressure, preventing bleeding-related distortion of vision by the acceleration of liquid flow, and eventually contributing toward the protection of the flexible device.
Nevertheless, there might be certain challenges during UAS placement. There are also risks, such as ureteral injury and the occurrence of ureteral stricture in the long term. However, considering the benefit/risk balance, RIRS is routinely performed in many clinics because of the ease provided by UAS.
Some problems might occur during the placement of UAS whose diameters vary between 9.5 and 14 Fr. In cases where UAS cannot be placed, manipulations can be used, such as ureteral balloon dilatation, providing access through a rigid ureteroscope with a guide wire, or dilatation with the inner sheath of the UAS, which may vary depending on the amount of personal experience. Despite such manipulations, if UAS placement is still unsuccessful, it is always more logical to place a double-J stent, enables passive dilatation, and postpone RIRS until the second operation.
This study will examine whether intramural ureteral resistance can be reduced or not and whether UAS placement can be facilitated using silodosin or not.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
This prospective study will be conducted on patients prepared for Retrograde intrarenal surgery presented to Ain Shams University Hospital. Patients will be randomized with 1:1 ratio into 2 equal groups.
Group A (the study group): Patients will receive silodosin 8 mg one tablet per day for 7 days before their scheduled retrograde intrarenal surgery.
silodosin is an alpha blocker which act to dilate the ureter to facilitate access sheath placement
This prospective study will be conducted on patients prepared for Retrograde intrarenal surgery presented to Ain Shams University Hospital. Patients will be randomized with 1:1 ratio into 2 equal groups.
Group A (the study group): Patients will receive silodosin 8 mg one tablet per day for 7 days before their scheduled retrograde intrarenal surgery.
Group B (the control group): Patients will receive Placebo for 7 days before their scheduled retrograde intrarenal surgery.
Time frame: intraoperative immediate diagnosis, at the beginning of surgery.
to assess the success of ureteric access sheath placement as follows:
Time frame: intraoperative diagnosis during the surgery from beginning of the surgery till the end of the procedure
time of the procedure will be recorded from the beginning of the diagnostic cystoscopy till placement of the flexible ureteroscopy
Time frame: till 7 days postoperative
regarding of both intraoperative complications in the form of ureteric mucosal tear, ureteric avulsion, residual stones, postoperative pain, dysuria, hematuria, and fever
Time frame: 1 day post operative
evaluation of the cost in both arms by comparing the price for the medication for 7 days on one arm. and the cost of the supplies needed intraoperative for ureteric dilatation or the need for another surgical session
Ain Shams University
Other
Effect of Perioperative Silodosin on Ureteric Dilatation in Retrograde Intrarenal Surgery
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02214836
Calculi, Female Urogenital Diseases
Seattle, Washington, United States
View Trial DetailsNCT07445646
Calculi, Female Urogenital Diseases
Zagazig, Egypt
View Trial DetailsNCT07555535
Airway Management, Female Urogenital Diseases
Yenimahalle, Ankara, Turkey (Türkiye)
View Trial DetailsNCT04490343
Calculi, Deep Learning Reconstruction
Amiens, France
View Trial Details